Experimental immune cell therapy shows promise for Tough-to-Treat colon cancer
Disease control
Completed
This completed Phase IIB trial tested an experimental immunotherapy called STIMVAX (AlloStim) in 29 adults with metastatic colorectal cancer that had not responded to two prior chemotherapy regimens. The treatment uses immune cells from healthy donors to try to fight the cancer. …
Phase: PHASE2 • Sponsor: Mirror Biologics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC